Federal grants to Collaborations Pharmaceuticals, Inc.
Collaborations Pharmaceuticals, Inc. in Fuquay Varina, North Carolina received $17.0 million in federal grants from fiscal 2021 to 2025, across 10 awards. Its largest program was Extramural Research Programs in the Neurosciences and Neurological Disorders, with $7.0 million. In fiscal 2025 it was awarded $3.8 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$17.0 million
- Awards10
- Awarded in FY 2025$3.8 million
- Largest award$4.0 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.5 million |
| FY 2022 | 7 | $5.0 million |
| FY 2023 | 5 | $3.8 million |
| FY 2024 | 3 | $2.9 million |
| FY 2025 | 3 | $3.8 million |
Programs that fund Collaborations Pharmaceuticals, Inc.
| Program | Awards | Amount |
|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 2 | $7.0 million |
| Environmental Health | 3 | $4.0 million |
| Biomedical Research and Research Training | 2 | $3.4 million |
| Scientific Research - Combating Weapons of Mass Destruction | 1 | $2.1 million |
| Allergy and Infectious Diseases Research | 1 | $295,096 |
| Drug Use and Addiction Research Programs | 1 | $256,220 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 9 | $15.0 million |
| Department of Defense | 1 | $2.1 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Manufacture of an intracerebroventricular enzyme replacement therapy for CLN1 batten disease - summary the neuronal ceroid lipofuscinoses (NCLS) are a group of incurable neurodegenerative storage disorders primarily affecting the brain and the retina of children and young adults, leading to dementia | Extramural Research Programs in the Neurosciences and Neurological Disorders | March 7, 2024 | $4.0 million |
| Manufacture of an intracerebroventricular enzyme replacement therapy for CLN1 batten disease - summary the neuronal ceroid lipofuscinoses (NCLS) are a group of incurable neurodegenerative storage disorders primarily affecting the brain and the retina of children and young adults, leading to dementia | Extramural Research Programs in the Neurosciences and Neurological Disorders | June 9, 2022 | $3.0 million |
| Using machine learning and in vitro methods to assess human metabolism of organophosphates pesticides and chemical warfare agents | Scientific Research - Combating Weapons of Mass Destruction | March 10, 2021 | $2.1 million |
| Machine learning approaches to predict acetylcholinesterase inhibition and model applications - summary organophosphorus (OP) compounds are one of the most common causes of poisoning worldwide. There are nearly 3 million poisonings per year resulting in three hundred thousand deaths. Ops bind to ace | Environmental Health | September 4, 2024 | $2.0 million |
| Megatrans ? Human transporter machine learning models - summary being able to predict interactions with important human transporters would be of value to new drug design to avoid compounds that interact with them and cause undesirable side effects. Conversely, some drug transporters can be used for | Biomedical Research and Research Training | September 2, 2022 | $1.7 million |
| Megatox for analyzing and visualizing data across different screening systems - project summary computational toxicology aims to use rules, models and algorithms based on prior data for specific endpoints, to enable the prediction of whether a new molecule will possess similar liabilities or not. In | Environmental Health | August 1, 2022 | $1.7 million |
| Centralized assay datasets for modelling support of small drug discovery organizations | Biomedical Research and Research Training | August 24, 2021 | $1.7 million |
| Preclinical development of a nipah virus inhibitor - project summary SARS-COV-2 has led to an increased urgency to develop treatments for additional emerging viruses and potentially provide broader spectrum antivirals in order to anticipate pandemic viruses. Nipah virus (NIV) is a bat-borne pathogen | Allergy and Infectious Diseases Research | September 15, 2023 | $295,096 |
| Machine learning approaches to predict acetylcholinesterase inhibition - summary acetylcholine (ACH) is a neurotransmitter at neuromuscular junctions and synapses in the autonomic and central nervous systems. It also functions as a signaling molecule in non-neuronal contexts related to cellular func | Environmental Health | December 9, 2021 | $256,385 |
| New therapeutic approaches to identifying molecules for opioid abuse treatment - project summary collaborations pharmaceuticals inc. Is a small business focused on developing treatments for difficult to treat diseases. The ongoing overreliance on opioids for chronic pain despite their poor ability t | Drug Use and Addiction Research Programs | April 12, 2022 | $256,220 |
Questions people ask
How much federal grant money does Collaborations Pharmaceuticals, Inc. get?
$17.0 million in 10 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Collaborations Pharmaceuticals, Inc. the most?
The Department of Health and Human Services, with $15.0 million in 9 awards. The Department of Defense follow.
What is Collaborations Pharmaceuticals, Inc.'s largest federal grant?
$4.0 million under Extramural Research Programs in the Neurosciences and Neurological Disorders, with its first action in the period on March 7, 2024. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Collaborations Pharmaceuticals, Inc.?
Its largest are Extramural Research Programs in the Neurosciences and Neurological Disorders, Environmental Health and Biomedical Research and Research Training.
Largest federal grant recipients in North Carolina · Federal grants in North Carolina